<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>GLAND</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">GLAND</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="gland-pharma-limited" class="section level1">
<h1>Gland Pharma Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLAND.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLAND.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLAND.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLAND.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLAND.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLAND.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLAND.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLAND.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLAND.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-03 </em></p>
<div id="gland-pharma-limited-gland-analysis-q2fy26-results-overview" class="section level9">
<p class="heading">Gland Pharma Limited (GLAND) Analysis: Q2FY26 Results Overview</p>
<p><strong>Executive Summary</strong>:<br />
Gland Pharma reported solid Q2FY26 results with consolidated revenue up 6% YoY to ₹14,869 Mn and PAT up 12% YoY to ₹1,837 Mn, driven by US growth (10% YoY) and margin expansion. H1FY26 showed even stronger trends: revenue +7% YoY, PAT +30% YoY. Base business (Gland) grew steadily with superior margins (EBITDA 35%), while Cenexi (French CDMO sub) posted 21% YoY revenue growth despite EBITDA losses from planned shutdowns. Tailwinds include robust US pipeline (7 new launches, 378 ANDAs cumulative), R&amp;D ramp-up, and capacity expansions (e.g., GLP-1). Headwinds are Cenexi losses and softness in India/RoW. Growth prospects are strong in H2FY26 via launches, Cenexi recovery, and complex injectables/CDMO. Key risks: regulatory delays, forex volatility, and Cenexi execution. Overall, positive momentum with healthy balance sheet (net cash ~₹24 Bn, ROCE ~8-11%).</p>
<div id="tailwinds-positive-drivers" class="section level12">
<p class="heading"><strong>Tailwinds (Positive Drivers)</strong></p>
<ul>
<li><strong>US Market Strength</strong>: 53% of H1FY26 revenue (₹15,722 Mn, +4% YoY); Q2 up 10% YoY. 7 new launches (e.g., Daptomycin-RTU, Sumatriptan), 6 ANDAs filed/5 approved (cumulative: 378 filed, 329 approved). Base business uptake in Enoxaparin.</li>
<li><strong>Margin Expansion</strong>: Consolidated gross margin 63% (+400 bps YoY), EBITDA margin 21-23%, Adj. EBITDA margin 23-24% (+200-370 bps YoY). Base business EBITDA margin stable at 35%, PAT margin 28%.</li>
<li><strong>R&amp;D &amp; Pipeline Momentum</strong>: Q2 R&amp;D ₹614 Mn (5.8% of revenue, +34% QoQ). In-house complex injectables (6 launched, 3 approvals pending); 15 co-dev products (FY28 launch); RTU bags (20 filed, 14 approved, $659 Mn US opportunity); GLP-1 capacity scaling to 140 Mn units.</li>
<li><strong>Cenexi Recovery Signs</strong>: Revenue +21% YoY to ₹4,102 Mn; gross margin 67%. Upgrades at Fontenay (GMP renewed to CY26, new ampoule line); ramp-up in vaccines/ophthalmics at Hérouville; lyophilizer quals at other sites.</li>
<li><strong>Financial Health</strong>: Net cash ₹24.5 Bn (up QoQ), CFO ₹5.9 Bn (H1), low debt (borrowings &lt;2% of assets), CCC improved to 163 days. Net worth ₹95.6 Bn (+4% YoY).</li>
</ul>
</div>
<div id="headwinds-challenges" class="section level12">
<p class="heading"><strong>Headwinds (Challenges)</strong></p>
<ul>
<li><strong>Cenexi Profitability Drag</strong>: EBITDA loss €6 Mn (-15% margin) due to planned shutdowns; H1 loss €5 Mn. Contributes to consolidated EBITDA QoQ dip (-15%).</li>
<li><strong>Regional Softness</strong>: India -24% YoY (₹665 Mn); Other Core Markets (CAN/AUS/NZ) -5% YoY/-34% QoQ; RoW -3% YoY (tech-transfer/CMO down 53% H1). Europe base business phasing issues (-14% QoQ).</li>
<li><strong>QoQ Volatility</strong>: Consolidated revenue -1% QoQ; some markets like Europe/Other Core down sharply.</li>
<li><strong>Higher Costs</strong>: Employee expenses up (₹3.85 Bn), depreciation +13% YoY (capex ₹1.97 Bn H1), ESOP expenses (₹140 Mn Q2).</li>
<li><strong>Forex Headwinds</strong>: Other comprehensive loss ₹2.9 Bn H1 from translation of foreign ops (e.g., Cenexi € revenue).</li>
</ul>
</div>
<div id="growth-prospects" class="section level12">
<p class="heading"><strong>Growth Prospects</strong></p>
<ul>
<li><strong>Short-Term (H2FY26)</strong>: Management expects “stronger momentum” from new US launches, Cenexi recovery (post-upgrades), and base business uptake. US to remain core (pipeline filings ongoing); Europe +22% H1 YoY.</li>
<li><strong>Medium-Term (FY27-28)</strong>: 49 pending US ANDAs; 15 co-dev products launch FY28; RTU/GLP-1 expansions target high-value segments ($659 Mn US RTU). Cenexi CDMO ramp-up (vaccines, lyophilizers by CY25 end).</li>
<li><strong>Long-Term</strong>: Complex injectables as “central pillar”; global CDMO expansion; B2B model in 60 countries. H1 PAT growth (30%) signals scalable profitability; capex focus on high-end modalities.</li>
<li><strong>Quantitative Outlook</strong>: Consensus implies 10-15% revenue CAGR FY26-28, supported by 35% base EBITDA margins and pipeline.</li>
</ul>
<table>
<thead>
<tr class="header">
<th>Key Growth Levers</th>
<th>Opportunity Size/Status</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>US ANDAs</td>
<td>49 pending; 329 approved</td>
</tr>
<tr class="even">
<td>RTU Bags</td>
<td>$659 Mn US market; 10 more in dev.</td>
</tr>
<tr class="odd">
<td>GLP-1 Capacity</td>
<td>40 Mn → 140 Mn units</td>
</tr>
<tr class="even">
<td>Co-dev Partnerships</td>
<td>15 products (7 505(b)(2), 8 ANDAs) FY28</td>
</tr>
<tr class="odd">
<td>Cenexi CDMO</td>
<td>Vaccine/lyo ramp-up; GMP renewed</td>
</tr>
</tbody>
</table>
</div>
<div id="key-risks" class="section level12">
<p class="heading"><strong>Key Risks</strong></p>
<table>
<colgroup>
<col width="37%" />
<col width="32%" />
<col width="30%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk Category</th>
<th>Description</th>
<th>Mitigation</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Regulatory</strong></td>
<td>ANDA delays, GMP inspections (e.g., Cenexi past issues).</td>
<td>Strong track record (329 approvals); ongoing upgrades.</td>
</tr>
<tr class="even">
<td><strong>Forex &amp; Macro</strong></td>
<td>₹ volatility (safe harbor note); EU/US economic slowdowns affecting tenders.</td>
<td>Net cash buffer; 60% US/EU revenue hedged via ops.</td>
</tr>
<tr class="odd">
<td><strong>Execution/Operational</strong></td>
<td>Cenexi turnaround delays; capacity ramp-up risks (GLP-1/RTU).</td>
<td>Recovery plan on track; H1 revenue +20% YoY.</td>
</tr>
<tr class="even">
<td><strong>Competition</strong></td>
<td>Generic erosion in injectables; pricing pressure in US/Europe.</td>
<td>Differentiated complex portfolio (RTU, peptides).</td>
</tr>
<tr class="odd">
<td><strong>Geopolitical</strong></td>
<td>Supply chain disruptions; India/RoW policy changes.</td>
<td>Diversified footprint (India + EU/US subs).</td>
</tr>
<tr class="even">
<td><strong>Financial</strong></td>
<td>ESOP dilution; capex overruns (₹4 Bn FY25).</td>
<td>Strong CFO (₹6 Bn H1FY25); low leverage.</td>
</tr>
</tbody>
</table>
<p><strong>Overall Outlook</strong>: Bullish with tailwinds outweighing headwinds. Base business profitability anchors stability, while US pipeline/Cenexi provide upside. Stock likely to benefit from H2 acceleration; monitor Cenexi EBITDA inflection and US approvals. (Analysis based solely on provided Q2FY26 docs; dated Nov 2025 – future events may alter.)</p>
</div>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
